

PACKAGE LEAFLET

VEINDOCANOL % 0,5 Solution for Injection

Applied into the vein

Sterile

10 mg Lauromacrogol 400 (Polidocanol) / 2 mL



Read all of this leaflet carefully before you receive this injection

- *Keep this leaflet. You may need to read it again.*
- *If you have any further questions, ask your doctor or pharmacist.*
- *Do not give to others; this drug is prescribed for you personally.*
- *If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.*
- *Followed the instruction written in this leaflet. Do not use **high** or **low** doses other than the recommended dose for the drug.*

In this leaflet:

1. What VEINDOCANOL % 0,5 is and what it is used for

2. Before you use VEINDOCANOL % 0,5

3. How to use VEINDOCANOL % 0,5

4. Possible side effects

5. How to store VEINDOCANOL % 0,5

1. What VEINDOCANOL % 0,5 is and what it is used for?

- VEINDOCANOL % 0,5 contains 10 mg of Lauromacrogol 400 as active ingredient on each ampoule.
- VEINDOCANOL % 0,5, clear, colorless to very faintly greenish yellow solution for injection and it is marketed as 5/2 mL ampoules in a box.
- VEINDOCANOL % 0,5 is included in a group of drugs that are administered by local injection and which provide complete closure of the vessel lumen (sclerosing)
- VEINDOCANOL 0,5% is used for sclerotherapy of spider veins and central veins of spider veins. Sclerotherapy is a method of completely closing the vessel lumen by injecting a sclerosing solution into the varicose vein

2. Before you use VEINDOCANOL % 0,5

- Sclerosans (drugs used for treatment with sclerotherapy) should never be injected into the artery. Because this application may cause widespread tissue death (necrosis), which may require surgical interruption of the relevant section. A vascular surgeon should be called immediately if such an event occurs.
- For all sclerosans, the facial area symptoms should be carefully evaluated because intravenous injection can lead to reversal of pressure in the arteries, thus causing irreversible vision loss (blindness).
- In certain areas of the body, such as the foot or wrist area, there may be a high risk of accidental injection into the artery. In these regions, only small amounts should be used during treatment and care should be taken.

Do not use VEINDOCANOL % 0,5

If:

- in patients with known allergy to Lauromacrogol 400 or any of the other ingredients of VEINDOCANOL % 0,5
- in bedridden patients or patients who are unable to walk
- in patients with severe arterial circulatory disorder (arterial occlusive disease Fontaine stage III and IV)
- in patients with vascular occlusion due to a local or detached blood clot (thromboembolic diseases)
- in patients with a high risk of vascular occlusions (thrombosis), e.g. patients with congenital predisposition to blood clots or with multiple risk factors such as the use of hormonal contraceptives (e.g. the pill) or hormone replacement therapy, overweight, smoking, extended periods of immobility, etc. in patients with acute severe disease (especially if untreated)

Take special care with VEINDOCANOL % 0,5

If:

- spider veins: in patients with arterial circulatory disorder (arterial occlusive disease Fontaine stage II)
- in patients with swollen legs with accumulation of aqueous fluid (leg oedema), if it cannot be influenced by compression
- in patients with febrile states
- in patients with inflammatory skin disease in the area of treatment
- in patients with symptoms of an occlusion of smallest and tiniest arterial vessels e.g. due to diabetes (microangiopathy) and impaired sensation (neuropathy)
- in patients with reduced mobility
- in patients with very poor general health
- in patients with attacks of laboured breathing (bronchial asthma) or strong predisposition to allergies

Please consult your doctor if these warnings are valid for you, even at any time in the past.

Pregnancy

Consult your doctor or pharmacist before using this medication.

There are no adequate data from the use of VEINDOCANOL % 0,5 in pregnant women. VEINDOCANOL % 0,5 should not be used during pregnancy unless clearly necessary. Studies in animals did not show any evidence of teratogenic effects.

If you notice that you are pregnant during your treatment, consult your doctor or pharmacist immediately.

Breast feeding

Consult your doctor or pharmacist before using this medication.

If you need to use VEINDOCANOL % 0,5 during lactation, it is advisable to suspend breast-feeding for 2-3 days, since investigations on the excretion of Lauromacrogol 400 in the breast milk have not been performed in humans.

Driving and using machines

No negative effects on the ability to drive and use machines are known for VEINDOCANOL % 0,5

Important information about some of the ingredients of VEINDOCANOL % 0,5

VEINDOCANOL % 0,5 contains 5% (v/v) alcohol. This must be taken into account in patients with previous alcoholism or treatment of alcoholism with disulfiram.

VEINDOCANOL % 0,5 contains potassium, but less than 1 mmol (39 mg) per ampoule, i.e. essentially 'potassium-free'.

VEINDOCANOL % 0,5 contains sodium, but less than 1 mmol (23 mg) per ampoule, i.e. essentially 'sodium-free'.

Using other medicines

- The active ingredient lauromacrogol 400 is also a local painkiller (local anaesthetic). Therefore, when combined with other anaesthetics, there is a risk of intensifying the effect of the anaesthetics on the cardiovascular system.

Please inform your doctor or pharmacist if you are currently using any prescription or non-prescription medication or if you have recently used it.

3. How to use VEINDOCANOL % 0,5?

Dosage

- Generally, the dose of 2 mg Lauromacrogol 400 per kg body weight per day should not be exceeded (for a patient weighing 70 kg, this would be a daily dose of up to 28 mL VEINDOCANOL % 0,5).
- When treating a patient with predisposition to hypersensitivity reactions for the first time, no more than one injection should be administered. Depending on the response, several injections may be administered in subsequent treatment sessions, provided that the maximum dose is not exceeded.
- Depending on the size of the area to be treated, 0.1-0.2 mL VEINDOCANOL % 0,5 are injected intravascularly

Method of administration

- Injections of VEINDOCANOL % 0,5 must be given strictly into the vessel (intravascularly)
- Refer to VEINDOCANOL % 0,5 for information on how to apply, at the end of this manual and for medical personnel.

Use in special population

Pediatric use:

No data

Geriatric use:

No data

Renal / Hepatic failure

No data

If you have an impression that VEINDOCANOL % 0,5 effect is too strong or too weak, talk to your doctor or pharmacist.

If more VEINDOCANOL % 0,5 is used than recommended

Overdose (caused by the volume or concentration being too high) may cause local tissue death (necrosis), especially after paravenous injection.

If you forget to use VEINDOCANOL % 0,5

Do not use a double dose to compensate for forgotten doses.

VEINDOCANOL Effects that may occur when the treatment is terminated with 0,5%

None.

4.Possible Side Effects

Like all medicines, VEINDOCANOL % 0,5 can cause side effects, although not everybody gets them. Local adverse reactions (e.g. necroses), especially of the skin and of the underlying tissue (and, in rare cases, of the nerves) were observed when treating varices in the leg after inadvertent injection into the surrounding tissue (paravenous injection). The risk increases with increasing Veindocanol concentrations and volumes.

In addition, the following adverse reactions were observed with the frequencies seen below:

Very common:	More than 1 out of 10 subjects treated
Common:	Less than 1 out of 10, but more than 1 out of 100 subjects treated
Uncommon:	Less than 1 out of 100, but more than 1 out of 1,000 subjects treated
Rare:	Less than 1 out of 1,000, but more than 1 out of 10,000 subjects treated
Very rare:	Less than 1 out of 10,000 subjects treated
Not known:	Cannot be estimated from the available data

Immune system disorders

Very rare: Anaphylactic shock (sudden life-threatening allergic reaction, symptoms are e.g. sudden breathing difficulties, dizziness, blood pressure drop); angioedema (symptoms include sudden swellings, especially in the face, e.g. of the eyelids, lips or larynx); hives (generalised urticaria); asthma (asthmatic attack).

Nervous system disorders

Very rare: Stroke (cerebrovascular accident), headache, migraine, local sensory disturbances (local paraesthesia), loss of consciousness, confusion, dizziness.

Eye disorders

Very rare: visual impairment (visual disturbance)

Cardiac disorders

Very rare: Cardiac arrest, fast or irregular heartbeats (palpitations)

Vascular disorders

Common: Occurrence of blood vessels in the area of sclerosis which were not visible prior to treatment (neovascularisation); bruise (haematoma)

Uncommon: Venous inflammation (superficial thrombophlebitis, phlebitis)

Rare: Deep vein thrombosis (possibly due to the underlying disease)

Very rare: Blockage of lung artery (pulmonary embolism); fainting (vasovagal syncope); circulatory collapse; inflammation of the blood vessel wall (vasculitis)

Respiratory, thoracic and mediastinal disorders

Very rare: Difficulty in breathing (dyspnoea); sensation of pressure in the chest; cough

Gastrointestinal disorders

Very rare: Taste disorders; nausea

Skin and subcutaneous tissue disorders

Common: Discolouration of the skin (hyperpigmentation); cutaneous haemorrhage (ecchymosis)

Uncommon: Allergic inflammation of the skin (dermatitis); hives (contact urticaria); skin reaction; redness of the skin (erythema)

Very rare: Excessive growth of hair (hypertrichosis) in the area of sclerotherapy

Musculoskeletal, connective tissue and bone disorders

Rare: Pain in extremity

General disorders and administration site conditions

Common: Pain at the injection site (short-term); thrombosis at the injection site (local intravascular blood clots)

Uncommon: Local tissue death (necrosis); induration of tissue; swelling

Very rare: Fever; hot flush; unusual weakness (asthenia); generally feeling unwell (malaise)

Investigations

Very rare: Abnormal blood pressure

Injury, poisoning and procedural complications

Uncommon: Nerve injury

If you encounter any side effects not mentioned in these instructions, please inform your doctor or pharmacist.

5. How to store VEINDOCANOL % 0,5

VEINDOCANOL % 0,5 should be kept out of the reach and sight of children

Do not store above 30°C.

Marketing Authorisation Holder:

C A Group Pharma İlaç İmalat İthalat İhracat Ve Sanayi Ticaret Anonim Şirketi

Öğüzlar Mah. 1397 Cad. No: 11 İç Kapı No: 1 Çankaya/ Ankara

Tel : 0533 550 51 23 Whatsapp hattı : 0535 715 92 09

E-posta: info@capharmagroup.com.tr

www.capharmagroup.com.tr

Manufacturer:

Rompharm İlaç Sanayi ve Tic. Ltd. Şti.

G.O.P Mah. COSB 5. Cad, No: 17

Çerkezköy / Tekirdağ

This leaflet was last approved in 20/01/2022.

THE FOLLOWING INFORMATION IS FOR THE HEALTH PERSONNEL WHO WILL APPLY THIS PRODUCT APPLICATION

- This product is for single use. The remaining part must be discarded after use
- Regardless of the way the needle is inserted into the vein (only when the patient is with the cannula or while the patient is sitting with a syringe ready for injection), Injections should only be carried out in a leg placed horizontally or elevated 30–45 ° above the horizontal.
- Injections of VEINDOCANOL % 0,5 must be given strictly into the vessel (intravascularly).
- Very fine needles (e.g. insulin needles) and smooth-moving syringes are used. The puncture is carried out with a small puncture angle until the needle is positioned intravenously.
- Depending on the degree and extent of the varices, several treatments may be required at intervals of 1-2 weeks.
- Once the injection site has been covered, a tight compression bandage or elastic stocking must be applied. After that, the patient should walk for 30 minutes, preferably within reach of the practice.
- When used for sclerotherapy of spider veins and central veins of spider veins, compression should be applied for 2-3 days after sclerotherapy of spider veins, otherwise for 5-7 days. For extensive varicosis, longer compression treatment with short traction bandages is recommended
- To make sure the bandage does not slip, especially on the thigh and conical limbs, a foam bandage support under the actual compression bandage is recommended.
- The success of sclerotherapy relies on thorough and careful follow-up compression treatment.

IMPORTANT PRECAUTIONS FOR USE

- Sclerosants must never be injected into an artery (intra-arterially) because this can cause extended tissue death (necrosis) which may necessitate amputation. A vascular surgeon must be called in immediately if any such incident occurs.
- An indication in the facial area must be strictly evaluated for all sclerosants because intravascular injection can lead to pressure reversal in the arteries and hence to irreversible visual disturbances (blindness).
- In certain body regions such as in the foot or malleolar region, the risk of inadvertent injection into an artery may be increased. In such areas, only small amounts should be used with particular care during treatment.